Research programme: bacterial DNA gyrase inhibitors - Vertex

Drug Profile

Research programme: bacterial DNA gyrase inhibitors - Vertex

Alternative Names: VRT-125853; VRT-752586; VX-692; VX-883; VXc-486/VXc-100

Latest Information Update: 27 May 2016

Price : $50

At a glance

  • Originator Vertex Pharmaceuticals
  • Class Benzimidazoles
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bacterial infections

Most Recent Events

  • 25 May 2016 Spero Therapeutics acquires VXc 486/VXc 100 from Vertex Pharmaceuticals
  • 17 Feb 2009 Preclinical development is ongoing in USA
  • 28 Feb 2007 Preclinical data added to the Bacterial Infections antimicrobial activity section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top